KR20020012315A - Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 - Google Patents

Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 Download PDF

Info

Publication number
KR20020012315A
KR20020012315A KR1020027000609A KR20027000609A KR20020012315A KR 20020012315 A KR20020012315 A KR 20020012315A KR 1020027000609 A KR1020027000609 A KR 1020027000609A KR 20027000609 A KR20027000609 A KR 20027000609A KR 20020012315 A KR20020012315 A KR 20020012315A
Authority
KR
South Korea
Prior art keywords
phenylamino
iodo
methyl
benzamide
difluoro
Prior art date
Application number
KR1020027000609A
Other languages
English (en)
Korean (ko)
Inventor
딕슨알리스테어
리케빈
핀녹로버트덴함
Original Assignee
로즈 암스트롱, 크리스틴 에이. 트러트웨인
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로즈 암스트롱, 크리스틴 에이. 트러트웨인, 워너-램버트 캄파니 filed Critical 로즈 암스트롱, 크리스틴 에이. 트러트웨인
Publication of KR20020012315A publication Critical patent/KR20020012315A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
KR1020027000609A 1999-07-16 2000-07-05 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 KR20020012315A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16
US60/144,292 1999-07-16
PCT/US2000/018347 WO2001005392A2 (en) 1999-07-16 2000-07-05 Method for treating chronic pain using mek inhibitors

Publications (1)

Publication Number Publication Date
KR20020012315A true KR20020012315A (ko) 2002-02-15

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027000609A KR20020012315A (ko) 1999-07-16 2000-07-05 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법

Country Status (16)

Country Link
EP (1) EP1202726A2 (es)
JP (1) JP2003504400A (es)
KR (1) KR20020012315A (es)
CN (1) CN1373660A (es)
AR (1) AR024732A1 (es)
AU (1) AU5786000A (es)
CA (1) CA2374052A1 (es)
CO (1) CO5300398A1 (es)
HU (1) HUP0202623A3 (es)
IL (1) IL147619A0 (es)
NZ (1) NZ515567A (es)
PE (1) PE20010545A1 (es)
PL (1) PL352684A1 (es)
TR (1) TR200200082T2 (es)
WO (1) WO2001005392A2 (es)
ZA (1) ZA200109907B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960614B2 (en) 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ES2407849T3 (es) 2002-03-13 2013-06-14 Array Biopharma, Inc. Derivados de bencimidazol alquilados N3 como inhibidores de MEK
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
WO2005035493A1 (ja) * 2003-10-08 2005-04-21 Teijin Pharma Limited アミノピロリジン誘導体の製造方法および中間体化合物
RU2352558C2 (ru) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Полиморфная форма n-[(r)-2,3-дигидроксипропокси]-3,4-дифтор-2-(2-фтор-4 йодфениламино)бензамида
DE602004031037D1 (de) 2003-11-19 2011-02-24 Array Biopharma Inc Heterocyclische inhibitoren von mek
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN102786482A (zh) 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
MY149960A (en) 2005-05-18 2013-11-15 Array Biopharma Inc 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
CA2927656C (en) 2005-10-07 2019-09-24 Exelixis, Inc. Mek inhibitors and methods of their use
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RU2481336C2 (ru) 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
EP2054418B1 (en) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
CA2671982C (en) 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
KR20150091196A (ko) 2007-07-05 2015-08-07 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN101868443A (zh) * 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
BRPI0821227A2 (pt) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
WO2009089459A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5539225B2 (ja) 2008-01-09 2014-07-02 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン
CA2742945A1 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
CN102574782B (zh) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
AU2011209586B2 (en) 2010-02-01 2016-01-21 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro- 4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo [4,5-b]pyridin-7-yloxy)-phenyl] -urea and related compounds and their use in therapy
US9045429B2 (en) 2010-10-29 2015-06-02 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
MX2013011333A (es) 2011-04-01 2014-04-16 Genentech Inc Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
EP2694072B1 (en) 2011-04-01 2017-11-29 Genentech, Inc. Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
MX2015004660A (es) 2012-10-12 2015-08-07 Exelixis Inc Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer.
EP3043790B1 (en) 2013-09-11 2021-05-26 The Administrators of the Tulane Educational Fund Novel anthranilic amides and the use thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
EP3368026A1 (en) 2015-10-27 2018-09-05 Acetylon Pharmaceuticals, Inc. Hdac inhibitors for the treatment of diabetic peripheral neuropathy
ES2883639T3 (es) 2017-10-17 2021-12-09 Atriva Therapeutics Gmbh Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas
CN114008013A (zh) * 2019-06-28 2022-02-01 哥本哈根大学 伴有睡眠障碍的cns病症的治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
KR20010014360A (ko) * 1997-07-01 2001-02-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 2-(4-브로모 또는 4-요오도 페닐아미노)벤조산 유도체 및ｍｅｋ 억제제로서의 그의 용도
ATE277895T1 (de) * 1997-07-01 2004-10-15 Warner Lambert Co 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
EP1143957A3 (en) * 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors

Also Published As

Publication number Publication date
NZ515567A (en) 2004-03-26
IL147619A0 (en) 2002-08-14
AR024732A1 (es) 2002-10-23
PE20010545A1 (es) 2001-06-04
HUP0202623A2 (hu) 2002-11-28
CN1373660A (zh) 2002-10-09
AU5786000A (en) 2001-02-05
WO2001005392A2 (en) 2001-01-25
HUP0202623A3 (en) 2003-03-28
TR200200082T2 (tr) 2002-04-22
CO5300398A1 (es) 2003-07-31
EP1202726A2 (en) 2002-05-08
CA2374052A1 (en) 2001-01-25
ZA200109907B (en) 2003-02-28
JP2003504400A (ja) 2003-02-04
WO2001005392A3 (en) 2001-07-19
PL352684A1 (en) 2003-09-08

Similar Documents

Publication Publication Date Title
KR20020012315A (ko) Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
DE60005688T2 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
KR20020015376A (ko) Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법
JP2003504399A (ja) Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
DE69928286T2 (de) Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
DE69928697T2 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DE69926914T2 (de) 1-heterozyklus-substituierte diarylaminen
US6506798B1 (en) 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
JP2003527379A (ja) Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
JP2002534491A (ja) 選択的ｍｅｋ阻害剤としての４−アリールアミノ、４−アリールオキシ、及び４−アリールチオジアリールアミン及びそれらの誘導体
CA2421502A1 (en) A method for treating allergies
US7030119B1 (en) Method for treating chronic pain using MEK inhibitors
JP2000212141A (ja) ジアリ―ルアミン
JP2004503535A (ja) インドールおよびベンゾイミダゾール１５−リポキシゲナーゼ阻害剤
JP2001055376A (ja) ジアリールアミン
JP2000212157A (ja) ジアリ―ルアミン

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid